Third-Quarter Indian Results Roundup: Alkem, Neuland, JB, Zydus And Natco
Several Indian firms have posted growth in their financial third quarters ended 31 December 2018. Alkem’s International sales manage to offset a slide in its domestic turnover, Neuland picks up momentum despite the impact of raw material price increases, while a better product mix in India works in JB’s favor. Zydus obtains a raft of US product approvals and lays out its approach for generics and biosimilars across the globe, while Natco focuses on complex generics in Canada and Brazil.
You may also be interested in...
Alvogen’s Lotus subsidiary and Cambrex are expanding their manufacturing capabilities in Taiwan and Canada respectively. As several firms reveal the results of FDA inspections, the agency slaps United Exchange Corporation with a warning letter.
Alvogen can sell in the US generic lenalidomide on a volume-limited basis after March 2022, and without volume limitations in early 2026, after settling patent litigation with Celgene relating to the originator’s Revlimid. Dr Reddy's has also settled in Canada.
A Q&A document has been released by the EMA outlining measures EU authorities are taking to prevent medicine shortages as a result of Brexit. Safety, medicine evaluation, clinical trials and supplies are all topics that are addressed in the text.